Last reviewed 2026-04-23 · How we verify

INR101

INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors.

INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

At a glance

Mechanism of action

It achieves this by targeting the vitamin K epoxide reductase complex 1 (VKORC1), which is essential for the recycling of vitamin K in the liver. By inhibiting VKORC1, INR101 reduces the production of vitamin K-dependent clotting factors, thereby preventing blood clots.

Approved indications

• Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

Common side effects

• International normalized ratio (INR) elevation
• Bleeding
• Gastrointestinal bleeding
• Hemorrhage
• Bruising
• Purpura

Key clinical trials

• Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer. (PHASE3)
• A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment (PHASE3)
• A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• INR101 CI brief — competitive landscape report
• INR101 updates RSS · CI watch RSS
• Yunhe Pharmaceutical (Tianjin) Co., Ltd portfolio CI